kringle-pharmaCo., Ltd.

NEWS

notice

Mar 08, 2021 Notice

Kringle Pharma today announces the addition of two clinical trial sites for Phase 3 of recombinant human HGF (KP-100IT) in acute spinal cord injury. The newly added sites are Japanese Red Cross Kobe Hospital as an acute care hospital and Aijinkai Rehabilitation Hospital as a convalescent rehabilitation hospital. New clinical sites expand opportunities for subject enrollment and confirming clinical feasibility of the KP-100IT therapy by a combination of the acute care and rehabilitation hospitals. Currently, five clinical sites including three national spinal cord injury centers are active for the ongoing Phase 3 trial in Japan. Detailed information about this Phase 3 trial is available at ClinicalTrials.gov using the identifier NCT04475224.

Kringle Pharma today announces the addition of two clinical trial sites for Phase 3 of recombinant human HGF (KP-100IT) in acute spinal cord injury. The newly added sites are Japanese Red Cross Kobe Hospital as an acute care hospital and Aijinkai Rehabilitation Hospital as a convalescent rehabilitation hospital. New clinical sites expand opportunities for subject enrollment and confirming clinical feasibility of the KP-100IT therapy by a combination of the acute care and rehabilitation hospitals. Currently, five clinical sites including three national spinal cord injury centers are active for the ongoing Phase 3 trial in Japan. Detailed information about this Phase 3 trial is available at ClinicalTrials.gov using the identifier NCT04475224.